• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在大鼠肠易激综合征 DCA 实验模型中 的有益作用。

Beneficial Effects of in the DCA Experimental Model of Irritable Bowel Syndrome in Rats.

机构信息

Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, 18071 Granada, Spain.

Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18071 Granada, Spain.

出版信息

Nutrients. 2022 Dec 21;15(1):24. doi: 10.3390/nu15010024.

DOI:10.3390/nu15010024
PMID:36615683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9824399/
Abstract

Limosilactobacillus fermentum CECT5716, a probiotic strain isolated from human milk, has reported beneficial effects on different gastrointestinal disorders. Moreover, it has shown its ability to restore altered immune responses, in association with microbiome modulation in different pathological conditions. Therefore, our aim was to assess the effects of a Limosilacbacillus fermentum CECT5716 in a rat experimental model of irritable bowel syndrome (IBS) that resembles human IBS. The experimental IBS was induced by deoxycholic acid (DCA) in rats and then, Limosilactobacillus fermentum CECT5716 (109 CFU/day/rat) was administered. Behavioral studies, hyperalgesia and intestinal hypersensitivity determinations were performed and the impact of the probiotic on the inflammatory and intestinal barrier integrity was evaluated. Additionally, the gut microbiota composition was analyzed. Limosilactobacillus fermentum CECT5716 attenuated the anxiety-like behavior as well as the visceral hypersensitivity and referred pain. Moreover, this probiotic ameliorated the gut inflammatory status, re-establishing the altered intestinal permeability, reducing the mast cell degranulation and re-establishing the gut dysbiosis in experimental IBS. Therefore, our results suggest a potential use of Limosilactobacillus fermentum CECT5716 in clinical practice for the management of IBS patients.

摘要

发酵乳杆菌 CECT5716 是从人乳中分离出来的益生菌株，已被报道对不同的胃肠道疾病有有益的影响。此外，它已显示出其在不同病理条件下调节微生物组的同时恢复改变的免疫反应的能力。因此，我们的目的是评估发酵乳杆菌 CECT5716 在类似于人类 IBS 的大鼠实验性 IBS 模型中的作用。通过在大鼠中用脱氧胆酸（DCA）诱导实验性 IBS，然后给予发酵乳杆菌 CECT5716（109 CFU/天/大鼠）。进行行为研究、痛觉过敏和肠道高敏感性测定，并评估益生菌对炎症和肠道屏障完整性的影响。此外，还分析了肠道微生物群的组成。发酵乳杆菌 CECT5716 减轻了焦虑样行为以及内脏高敏感性和牵涉痛。此外，这种益生菌改善了肠道炎症状态，重新建立了改变的肠道通透性，减少了肥大细胞脱颗粒，并在实验性 IBS 中重新建立了肠道菌群失调。因此，我们的结果表明，发酵乳杆菌 CECT5716 在临床实践中可能用于管理 IBS 患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/952d4158459d/nutrients-15-00024-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/25c563d3fcb7/nutrients-15-00024-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/d6a552e4d183/nutrients-15-00024-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/4b40b873d662/nutrients-15-00024-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/9c8deca0465a/nutrients-15-00024-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/4d686bf610b6/nutrients-15-00024-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/632e6ebc473b/nutrients-15-00024-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/1d5c5e133152/nutrients-15-00024-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/b01068d70868/nutrients-15-00024-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/47a1dd11372e/nutrients-15-00024-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/109dc663cdca/nutrients-15-00024-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/952d4158459d/nutrients-15-00024-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/25c563d3fcb7/nutrients-15-00024-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/d6a552e4d183/nutrients-15-00024-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/4b40b873d662/nutrients-15-00024-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/9c8deca0465a/nutrients-15-00024-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/4d686bf610b6/nutrients-15-00024-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/632e6ebc473b/nutrients-15-00024-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/1d5c5e133152/nutrients-15-00024-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/b01068d70868/nutrients-15-00024-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/47a1dd11372e/nutrients-15-00024-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/109dc663cdca/nutrients-15-00024-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a552/9824399/952d4158459d/nutrients-15-00024-g011.jpg

相似文献

1
Beneficial Effects of in the DCA Experimental Model of Irritable Bowel Syndrome in Rats.在大鼠肠易激综合征 DCA 实验模型中 的有益作用。
Nutrients. 2022 Dec 21;15(1):24. doi: 10.3390/nu15010024.
2
CECT5716: Clinical Potential of a Probiotic Strain Isolated from Human Milk.CECT5716：从人乳中分离出的益生菌菌株的临床潜力。
Nutrients. 2023 May 6;15(9):2207. doi: 10.3390/nu15092207.
3
Lactobacillus fermentum CECT5716 ameliorates high fat diet-induced obesity in mice through modulation of gut microbiota dysbiosis.发酵乳杆菌 CECT5716 通过调节肠道菌群失调改善高脂肪饮食诱导的肥胖小鼠模型。
Pharmacol Res. 2021 May;167:105471. doi: 10.1016/j.phrs.2021.105471. Epub 2021 Jan 30.
4
Lactobacillus fermentum CECT5716 supplementation in rats during pregnancy and lactation affects mammary milk composition.妊娠和哺乳期大鼠补充发酵乳杆菌 CECT5716 会影响乳腺乳汁成分。
J Dairy Sci. 2020 Apr;103(4):2982-2992. doi: 10.3168/jds.2019-17384. Epub 2020 Jan 31.
5
CECT5716: Mechanisms and Therapeutic Insights.CECT5716：机制与治疗新视角。
Nutrients. 2021 Mar 21;13(3):1016. doi: 10.3390/nu13031016.
6
Potentially Probiotic Limosilactobacillus fermentum Fruit-Derived Strains Alleviate Cardiometabolic Disorders and Gut Microbiota Impairment in Male Rats Fed a High-Fat Diet.具有潜在益生菌特性的发酵乳杆菌水果源菌株可缓解高脂饮食雄性大鼠的心脏代谢紊乱和肠道微生物群损伤
Probiotics Antimicrob Proteins. 2022 Apr;14(2):349-359. doi: 10.1007/s12602-021-09889-y. Epub 2022 Jan 23.
7
Safety assessment of Lactobacillus fermentum CECT5716, a probiotic strain isolated from human milk.发酵乳杆菌CECT5716（一种从人乳中分离出的益生菌菌株）的安全性评估。
J Dairy Res. 2009 May;76(2):216-21. doi: 10.1017/S0022029909004014. Epub 2009 Mar 13.
8
Intestinal anti-inflammatory and visceral analgesic effects of a extract in an experimental model of irritable bowel syndrome in rats.某提取物在大鼠肠易激综合征实验模型中的肠道抗炎和内脏镇痛作用。
Front Pharmacol. 2022 Sep 2;13:967644. doi: 10.3389/fphar.2022.967644. eCollection 2022.
9
Probiotic from human breast milk, Lactobacillus fermentum, promotes growth in animal model of chronic malnutrition.来自人母乳的益生菌发酵乳杆菌可促进慢性营养不良动物模型的生长。
Pediatr Res. 2020 Sep;88(3):374-381. doi: 10.1038/s41390-020-0774-0. Epub 2020 Feb 5.
10
The viability of Lactobacillus fermentum CECT5716 is not essential to exert intestinal anti-inflammatory properties.发酵乳杆菌CECT5716的生存能力对于发挥肠道抗炎特性并非必不可少。
Food Funct. 2015 Apr;6(4):1176-84. doi: 10.1039/c4fo00938j.

引用本文的文献

1
The Potential Role of -Related Mast Cell Activation in the Progression from Gastroesophageal Reflux to Barrett's Esophagus and Esophageal Adenocarcinoma.与……相关的肥大细胞激活在胃食管反流进展为巴雷特食管和食管腺癌过程中的潜在作用 。 注：原文中“-Related”处有缺失内容，以上是根据现有内容尽量准确翻译的结果。
Microorganisms. 2025 Aug 12;13(8):1883. doi: 10.3390/microorganisms13081883.
2
Microbiome contributions to pain: a review of the preclinical literature.微生物群对疼痛的影响：临床前文献综述
Pain. 2025 Feb 1;166(2):262-281. doi: 10.1097/j.pain.0000000000003376. Epub 2024 Sep 10.
3
Exploring Therapeutic Advances: A Comprehensive Review of Intestinal Microbiota Modulators.

本文引用的文献

1
Colonic mucosal eosinophilia and immunohistochemical expression of COX-2 and NF-kB in patients with irritable bowel syndrome.肠易激综合征患者结肠黏膜嗜酸性粒细胞增多及COX-2和NF-κB的免疫组化表达
Eur J Gastroenterol Hepatol. 2022 May 1;34(5):512-517. doi: 10.1097/MEG.0000000000002363.
2
Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M).综述文章：腹泻型肠易激综合征（IBS-D）和 IBS 混合表型（IBS-M）的当前和未来治疗方法。
Aliment Pharmacol Ther. 2021 Dec;54 Suppl 1:S63-S74. doi: 10.1111/apt.16625.
3
Pubertal probiotics mitigate lipopolysaccharide-induced programming of the hypothalamic-pituitary-adrenal axis in male mice only.
探索治疗进展：肠道微生物群调节剂的全面综述
Antibiotics (Basel). 2024 Aug 1;13(8):720. doi: 10.3390/antibiotics13080720.
4
A novel Bacillus aerolatus CX253 attenuates inflammation induced by Streptococcus pneumoniae in childhood and pregnant rats by regulating gut microbiome.一株新型 Aerolatus 芽孢杆菌 CX253 通过调节肠道微生物组减轻儿童和孕鼠肺炎链球菌引起的炎症。
Cell Mol Life Sci. 2024 Jul 29;81(1):319. doi: 10.1007/s00018-024-05232-0.
5
CECT5716: Clinical Potential of a Probiotic Strain Isolated from Human Milk.CECT5716：从人乳中分离出的益生菌菌株的临床潜力。
Nutrients. 2023 May 6;15(9):2207. doi: 10.3390/nu15092207.
青春期益生菌仅可减轻雄性小鼠脂多糖诱导的下丘脑-垂体-肾上腺轴编程。
Brain Res Bull. 2021 Dec;177:111-118. doi: 10.1016/j.brainresbull.2021.09.017. Epub 2021 Sep 22.
4
Evaluation of the Effect of CECT5716 on Gastrointestinal Infections in Infants: A Systematic Review and Meta-Analysis.CECT5716对婴儿胃肠道感染影响的评估：一项系统评价与Meta分析
Microorganisms. 2021 Jun 30;9(7):1412. doi: 10.3390/microorganisms9071412.
5
Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation.便秘型肠易激综合征和慢性特发性便秘的治疗选择综述
Int J Gen Med. 2021 Apr 21;14:1457-1468. doi: 10.2147/IJGM.S274568. eCollection 2021.
6
Diagnosis and Treatment of Irritable Bowel Syndrome: A Review.肠易激综合征的诊断与治疗：综述
JAMA. 2021 Mar 2;325(9):865-877. doi: 10.1001/jama.2020.22532.
7
Regulation of Intestinal Barrier Function by Microbial Metabolites.微生物代谢物对肠道屏障功能的调节。
Cell Mol Gastroenterol Hepatol. 2021;11(5):1463-1482. doi: 10.1016/j.jcmgh.2021.02.007. Epub 2021 Feb 18.
8
Lactobacillus fermentum CECT5716 ameliorates high fat diet-induced obesity in mice through modulation of gut microbiota dysbiosis.发酵乳杆菌 CECT5716 通过调节肠道菌群失调改善高脂肪饮食诱导的肥胖小鼠模型。
Pharmacol Res. 2021 May;167:105471. doi: 10.1016/j.phrs.2021.105471. Epub 2021 Jan 30.
9
Mast Cell Regulation and Irritable Bowel Syndrome: Effects of Food Components with Potential Nutraceutical Use.肥大细胞调控与肠易激综合征：具有潜在营养保健品用途的食物成分的影响。
Molecules. 2020 Sep 20;25(18):4314. doi: 10.3390/molecules25184314.
10
Rifaximin Improves Visceral Hyperalgesia via TRPV1 by Modulating Intestinal Flora in the Water Avoidance Stressed Rat.利福昔明通过调节水回避应激大鼠的肠道菌群，经由瞬时受体电位香草酸亚型1（TRPV1）改善内脏痛觉过敏。
Gastroenterol Res Pract. 2020 Jul 20;2020:4078681. doi: 10.1155/2020/4078681. eCollection 2020.